Agendia Opens CLIA-Registered U.S. Genomics Laboratory

Huntington Beach, California and Amsterdam (ots/PRNewswire) -

- Agendia Increases U.S. Footprint with Domestic Executive Team
and Operations

Agendia, a world leader in molecular cancer diagnostics, today
announced the opening of its U.S. clinical genomics laboratory in
Huntington Beach, CA. The laboratory is fully-licensed and compliant
with the Clinical Laboratory Improvements Amendments (CLIA) as
administered by the Centers for Medicare and Medicaid Services (CMS).

In addition to opening its U.S. cancer genomics laboratory,
Agendia has over the past months made several key additions to its
domestic-based senior executive team. The team consists of Dr.
Richard Bender, Chief Medical Officer, Mr. Daniel Forche, Vice
President of Sales & Marketing, Mr. Alan B. Carter, Vice President of
Global Business Development, and pathologist Dr. Chynel Henning,
Laboratory Director.

"Our new genomics lab's capacity will allow us to meet the
increasing demand for MammaPrint across the United States and give
physicians and patients optimal test result turnaround and unmatched
service and support," noted Jan Groen, Ph.D., Chief Operating
Officer. "This expansion places us in an excellent position to
continue making advancements in molecular cancer diagnostics and
equip oncologists with powerful tools to use in the fight against
breast cancer."

Dr. Bernhard Sixt, President and Chief Executive Officer, added,
"the opening of the Huntington Beach laboratory and the appointment
of our U.S.-based commercial team provide a strong basis for our U.S.
operations and for Agendia's next phase of growth. Our enhanced
domestic capabilities will help us to further drive adoption of
MammaPrint, and place us in an even better position to collaborate
with a growing number of clinical, academic, and industrial partners
here in the U.S."

Dr. Bender has more than 30 years of medical and professional
experience as a practicing oncologist and director of several
oncology programs. Dr. Bender has served as Medical Director of the
Hematology/Oncology Program at Quest Diagnostics, Director of Medical
Oncology and Hematology at Kaiser Permanente Medical Group, Director
of Strategic Development in Medical Oncology/Hematology at Johnson &
Johnson, and as an investigator at the National Cancer Institute and
Scripps Clinic and Research Foundation. Currently, Dr. Bender serves
as an expert reviewer in oncology for the Medical Board of
California, co-Editor of Anti-Cancer Drugs, an international journal
on anti-cancer agents, and as a clinical instructor in medicine at
the University of California, Irvine School of Medicine.

Mr. Forche brings more than 18 years of sales, marketing and
commercial leadership experience in the diagnostics arena. Prior to
joining Agendia, Mr. Forche was the Senior Vice President of Sales
and Marketing for Insight Health Corporation, a national leader in
diagnostic imaging services. He also served as Vice President of
Marketing at US LABS, an industry leader in cancer diagnostic and
genomic testing services, and has held sales and marketing management
roles at Ventana Medical Systems (now Roche) and Abbott Laboratories.

Mr. Carter joins Agendia with 25 years of global business
development experience from a number of top-tier life sciences
companies such as BioTrove, Celera, Applied Biosystems, and Perkin
Elmer. At Agendia, he oversees ongoing strategic alliances within the
bio-pharmaceutical sector and collaboration with partners interested
in Agendia's expanding molecular diagnostics portfolio.

Chynel Henning, M.D., Ph.D., FASCP, FCAP, joins Agendia with more
than 30 years of experience as a laboratory director. He is currently
also Director of National Cyto-Path Laboratories and Professional
Pathology Medical Group Laboratory, both in Long Beach, California;
and Director of the Laboratory and Department of Pathology at the
Miracle Mile Medical Center, Los Angeles. Dr. Henning is a Fellow of
the American Society of Clinical Pathologists and the College of
American Pathologists.

Ongoing research and development commitments continue to augment
Agendia's ability to accurately predict breast cancer recurrence and
sub-typing, and help physicians tailor individual treatment plans to
their patients. Agendia's goal is to provide women with answers to
crucial treatment questions, such as how their breast cancer will
respond to targeted therapies or various chemotherapy regimens.

For more information, please visit http://www.agendia.com

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatment within reach of patients. Building on a cutting edge
genomics platform for tumor gene expression profiling, the company's
tests aim to help physicians more accurately tailor cancer therapy.
The company markets four products, with several new genomic tests in
development. Agendia collaborates with pharmaceutical companies in
the development of highly effective personalized drugs in the area of
oncology. Agendia was awarded the 2008 North American Oncology
Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan.
Agendia is based in Huntington Beach, California, and in Amsterdam,
The Netherlands. For more information please visit
http://www.agendia.com.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
MEDIA CONTACTS: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
hans.herklots@agendia.com; Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, +1-917-975-3191
Mobile, vdelva@ricochetpr.com